227 related articles for article (PubMed ID: 36280013)
21. Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease.
Zhang YN; Fowler KJ; Boehringer AS; Montes V; Schlein AN; Covarrubias Y; Wolfson T; Hong CW; Valasek MA; Andre MP; Loomba R; Sirlin CB
Eur Radiol; 2022 Apr; 32(4):2457-2469. PubMed ID: 34854929
[TBL] [Abstract][Full Text] [Related]
22. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.
Chan WK; Nik Mustapha NR; Mahadeva S
Hepatol Int; 2015 Oct; 9(4):594-602. PubMed ID: 25788185
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
[TBL] [Abstract][Full Text] [Related]
24. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
[TBL] [Abstract][Full Text] [Related]
25. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
[TBL] [Abstract][Full Text] [Related]
26. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.
Petta S; Vanni E; Bugianesi E; Di Marco V; Cammà C; Cabibi D; Mezzabotta L; Craxì A
Liver Int; 2015 May; 35(5):1566-73. PubMed ID: 24798049
[TBL] [Abstract][Full Text] [Related]
27. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.
Han MAT; Vipani A; Noureddin N; Ramirez K; Gornbein J; Saouaf R; Baniesh N; Cummings-John O; Okubote T; Setiawan VW; Rotman Y; Loomba R; Alkhouri N; Noureddin M
Liver Int; 2020 Sep; 40(9):2242-2251. PubMed ID: 32652744
[TBL] [Abstract][Full Text] [Related]
28. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
[TBL] [Abstract][Full Text] [Related]
29. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
Sanyal AJ; Foucquier J; Younossi ZM; Harrison SA; Newsome PN; Chan WK; Yilmaz Y; De Ledinghen V; Costentin C; Zheng MH; Wai-Sun Wong V; Elkhashab M; Huss RS; Myers RP; Roux M; Labourdette A; Destro M; Fournier-Poizat C; Miette V; Sandrin L; Boursier J
J Hepatol; 2023 Feb; 78(2):247-259. PubMed ID: 36375686
[TBL] [Abstract][Full Text] [Related]
30. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
[TBL] [Abstract][Full Text] [Related]
31. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis.
Singh S; Venkatesh SK; Loomba R; Wang Z; Sirlin C; Chen J; Yin M; Miller FH; Low RN; Hassanein T; Godfrey EM; Asbach P; Murad MH; Lomas DJ; Talwalkar JA; Ehman RL
Eur Radiol; 2016 May; 26(5):1431-40. PubMed ID: 26314479
[TBL] [Abstract][Full Text] [Related]
32. Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study.
Loomba R; Cui J; Wolfson T; Haufe W; Hooker J; Szeverenyi N; Ang B; Bhatt A; Wang K; Aryafar H; Behling C; Valasek MA; Lin GY; Gamst A; Brenner DA; Yin M; Glaser KJ; Ehman RL; Sirlin CB
Am J Gastroenterol; 2016 Jul; 111(7):986-94. PubMed ID: 27002798
[TBL] [Abstract][Full Text] [Related]
33. Transient Elastography Is the Best-Performing Non-Invasive Test of Liver Fibrosis in Obese Asian Patients with Non-Alcoholic Fatty Liver Disease: A Pilot, Cross-Sectional Study.
Kalaiyarasi K; Sanchalika A; Hsien Min L; Wei Ming Y; Vishalkumar S; Kuo Chao Y; Jee Keem L; Sameer J; Terence HCW; Yen Ping T
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256429
[No Abstract] [Full Text] [Related]
34. Prospective Evaluation of Virtual MR Elastography With Diffusion-Weighted Imaging in Subjects With Nonalcoholic Fatty Liver Disease.
Hanniman E; Costa AF; Bowen CV; Abdolell M; Stueck A; McLeod M; Peltekian K; Rioux J; Clarke SE
J Magn Reson Imaging; 2022 Nov; 56(5):1448-1456. PubMed ID: 35285996
[TBL] [Abstract][Full Text] [Related]
35. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
36. Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease.
Inada K; Tamaki N; Kurosaki M; Kirino S; Yamashita K; Hayakawa Y; Higuchi M; Takaura K; Kaneko S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
J Gastroenterol Hepatol; 2022 Sep; 37(9):1726-1731. PubMed ID: 35587726
[TBL] [Abstract][Full Text] [Related]
37. Comparing the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score with transient elastography scores of people with non-alcoholic fatty liver disease.
Cox B; Trasolini R; Galts C; Yoshida EM; Marquez V
Can Liver J; 2021; 4(3):275-282. PubMed ID: 35992256
[TBL] [Abstract][Full Text] [Related]
38. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting.
Congly SE; Shaheen AA; Swain MG
PLoS One; 2021; 16(5):e0251741. PubMed ID: 34019560
[TBL] [Abstract][Full Text] [Related]
39. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
[TBL] [Abstract][Full Text] [Related]
40. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System.
Vilar-Gomez E; Lou Z; Kong N; Vuppalanchi R; Imperiale TF; Chalasani N
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2305-2314.e12. PubMed ID: 32289535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
